Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Europe Approves Valcyte (Valganciclovir) For Prevention Of Cytomegalovirus After Organ Transplant Transplant recipients set to benefit from Valcyte's much simpler once a day regimeLONDON, ENGLAND -- May 23, 2003 -- Roche's antiviral drug Valcyte (valganciclovir) received confirmation that the Mutual Recognition Procedure has been completed for the prevention of cytomegalovirus (CMV) disease. CMV is a potentially fatal infection that frequently threatens the health of people who have received a solid organ transplantation. The recommendation by the European member states to approve Valcyte for this new indication means that patients can soon be prescribed an effective CMV preventative therapy with a much simpler regimen than the current standard therapy. Valcyte delivers the same safety and efficacy as the current gold standard therapy, ganciclovir, but with the added advantage of a simpler, oral, once-daily, patient-friendly dosing regimen - two tablets taken once daily compared to twelve capsules taken in three doses daily. Welcoming the news of Valcyte's approval, Dr Mark Pescovitz, Professor of Surgery and Microbiology/Immunology, and Director of Transplant Surgery at Indiana University, USA, says: "We know the potential dangers of CMV disease. With Valcyte's approval, I feel confident we can now provide patient-friendly, convenient oral preventative therapy with efficacy as good as the current gold standard, Cymevene." "CMV disease continues to pose a real and life-long threat to the recovery and health of many solid organ transplantation patients," continues Dr Pescovitz. "The clinical impact of this threat can include hepatitis, pneumonia and chronic injury of the grafted organ." The European approval is based on data from a 6 month non-inferiority study of 372-high risk patients that shows that a 900mg once-daily dose of Valcyte is as consistent as a 1000mg three times per day dose of ganciclovir in preventing CMV disease, with a similar safety profile. "Valcyte's approval reinforces Roche's ongoing commitment to develop innovative therapies in post-transplantation care," says Hari Kumar, Global Leader Valcyte, Roche. "The simpler dosing regimen of Valcyte is a further improvement for patients in whom compliance can be an issue." About CMV CMV is a member of the herpes family of viruses. In individuals with healthy immune systems, after initial infection, CMV can exist in the body in a dormant state. However, among individuals with compromised immune systems, such as patients taking post-transplant immunosuppressants or those with HIV/AIDS, the virus can become active causing disease and organ damage. CMV disease occurs in up to 40% of organ transplant recipients and is responsible for a substantial number of deaths and graft failures in these patients. CMV disease may affect the transplanted organ by causing direct as well as insidious damage, and/or by developing infection by opportunistic pathogens. About Valcyte Valcyte, a prodrug of Roche's existing anti-CMV treatment, Cymevene, was developed in response to the need for more convenient and patient-friendly administration of ganciclovir. Cymevene is the number one treatment of choice for CMV disease worldwide. References: 1 Rubin RH, Wolfson JH, Cosimi AB, et al. Infection in the renal transplant patient. Am J Med 1981; 70:405-411 2 Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10:86-124 SOURCE: Ketchum E-mail this page to a friend or colleague! To print, use this version